short engagement, selective CDK9 kinase inh.

IV treatment in Ph. I for RR-heme cancers

shortened t1/2 from prior preclin. candidate

J. Med. Chem., Dec. 11, 2020

AstraZeneca, Cambridge, UK / Boston, MA

AstraZeneca selective CDK9 kinase inhibitor


 become a member to continue reading

Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.

  • Stay up-to-date and save more time with exclusive members-only content
  • On-board new team members with educational content and case studies
  • Generate ideas and discussion with easy-to-read slide decks
  • Generate ideas and discussion with easy-to-read slide decks